Prediction of multidimensional drug dose responses based on measurements of drug pairs

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 37, 2016, Pages 10442-10447

  Zimmer, Anat ^a   Katzir, Itay ^a   Dekel, Erez ^a   Mayo, Avraham E ^a   Alon, Uri ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cancer treatment|mechanism free formula; Drug cocktails; Drug combinations; Predictive formula

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; CISPLATIN; DOXORUBICIN; DOXYCYCLINE; ERYTHROMYCIN; LINCOMYCIN; OFLOXACIN; PACLITAXEL; SALICYLIC ACID; TETRACYCLINE; TRIMETHOPRIM;

CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MEASUREMENT ACCURACY; PREDICTIVE VALUE; PRIORITY JOURNAL; NEOPLASM; THEORETICAL MODEL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MODELS, THEORETICAL; NEOPLASMS;

EID: 84986879765     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1606301113     Document Type: Article

References (49)

1. Chait R, Vetsigian K, Kishony R (2011) What counters antibiotic resistance in nature? Nat Chem Biol 8(1):2-5.
2. DeVita VT, Jr, Young RC, Canellos GP (1975) Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 35(1):98-110.
3. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2(9):458-466.
4. Hopkins AL (2008) Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 4(11):682-690.
5. Lehár J, et al. (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27(7):659-666.
6. Xu L, et al. (2012) Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 72(13):3302-3311.
7. Bock C, Lengauer T (2012) Managing drug resistance in cancer: Lessons from HIV therapy. Nat Rev Cancer 12(7):494-501.
8. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 13(10):714-726.
9. Hu C-MJ, Zhang L (2012) Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 83(8):1104-1111.
10. Chou T-C, Talalay P (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
11. Held MA, et al. (2013) Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3(1):52-67.
12. Schuldiner M, et al. (2005) Exploration of the function and organization of the yeast early secretory pathway through an epistatic miniarray profile. Cell 123(3):507-519.
13. Stylianou M, et al. (2014) Antifungal application of nonantifungal drugs. Antimicrob Agents Chemother 58(2):1055-1062.
14. Wood KB, Wood KC, Nishida S, Cluzel P (2014) Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells. Cell Reports 6(6):1073-1084.
15. Bliss CI (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26(3):585-615.
16. Bliss CI (1956) The calculation of microbial assays. Bacteriol Rev 20(4):243-258.
17. Chait R, Craney A, Kishony R (2007) Antibiotic interactions that select against resistance. Nature 446(7136):668-671.
18. Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3(6):285-290.
19. Berenbaum MC (1989) What is synergy? Pharmacol Rev 41(2):93-141.
20. Bollenbach T, Quan S, Chait R, Kishony R (2009) Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. Cell 139(4):707-718.
21. Yeh P, Tschumi AI, Kishony R (2006) Functional classification of drugs by properties of their pairwise interactions. Nat Genet 38(4):489-494.
22. Feala JD, et al. (2010) Systems approaches and algorithms for discovery of combinatorial therapies. Wiley Interdiscip Rev Syst Biol Med 2(2):181-193.
23. Calzolari D, et al. (2008) Search algorithms as a framework for the optimization of drug combinations. PLOS Comput Biol 4(12):e1000249.
24. Dancey JE, Chen HX (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5(8):649-659.
25. Lundstedt T, et al. (1998) Experimental design and optimization. Chemom Intell Lab Syst 42(1-2):3-40.
26. Bedard PL, Hansen AR, Ratain MJ, Siu LL (2013) Tumour heterogeneity in the clinic. Nature 501(7467):355-364.
27. Blom K, Nygren P, Alvarsson J, Larsson R, Andersson CR (2016) Ex vivo assessment of drug activity in patient tumor cells as a basis for tailored cancer therapy. J Lab Autom 21(1):178-187.
28. Pemovska T, et al. (2013) Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 3(12):1416-1429.
29. Sequist LV, et al. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 22(12):2616-2624.
30. Bordbar A, Monk JM, King ZA, Palsson BO (2014) Constraint-based models predict metabolic and associated cellular functions. Nat Rev Genet 15(2):107-120.
31. Janes KA, et al. (2005) A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 310(5754):1646-1653.
32. Wood K, Nishida S, Sontag ED, Cluzel P (2012) Mechanism-independent method for predicting response to multidrug combinations in bacteria. Proc Natl Acad Sci USA 109(30):12254-12259.
33. Farha MA, Brown ED (2015) Unconventional screening approaches for antibiotic discovery. Ann N Y Acad Sci 1354(1):54-66.
34. Guimerà R, Sales-Pardo M (2013) A network inference method for large-scale unsupervised identification of novel drug-drug interactions. PLOS Comput Biol 9(12): e1003374.
35. Park M, Nassar M, Vikalo H (2013) Bayesian active learning for drug combinations. IEEE Trans Biomed Eng 60(11):3248-3255.
36. Weiss A, et al. (2015) Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis 18(3):233-244.
37. Weiss A, et al. (2015) A streamlined search technology for identification of synergistic drug combinations. Sci Rep 5:14508.
38. Chou T-C (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3): 621-681.
39. Chou T-C (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440-446.
40. Hahn SM, et al. (1993) Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer 72(9):2705-2711.
41. Huizing MT, et al. (1995) Taxanes: A new class of antitumor agents. Cancer Invest 13(4):381-404.
42. Kroep JR, et al. (2000) Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer 83(8):1069-1076.
43. Otwinowski J, Nemenman I (2013) Genotype to phenotype mapping and the fitness landscape of the E. coli lac promoter. PLoS ONE 8(5):e61570.
44. Schneidman E, Berry MJ, Segev R, Bialek W (2006) Weak pairwise correlations imply strongly correlated network states in a neural population. Nature 440:1007-1012.
45. Lehár J, Krueger A, Zimmermann G, Borisy A (2008) High-order combination effects and biological robustness. Mol Syst Biol 4:215.
46. Zimmermann GR, Lehár J, Keith CT (2007) Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discov Today 12(1-2):34-42.
47. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R (2009) Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 7(6):460-466.
48. Cohen SP, Levy SB, Foulds J, Rosner JL (1993) Salicylate induction of antibiotic resistance in Escherichia coli: Activation of the mar operon and a mar-independent pathway. J Bacteriol 175(24):7856-7862.
49. Price CT, Lee IR, Gustafson JE (2000) The effects of salicylate on bacteria. Int J Biochem Cell Biol 32(10):1029-1043.